Lee Ainslie's UTHR Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 1,219 shares of United Therapeutics Corporation (UTHR) worth $660,564, representing 0.01% of the portfolio. First purchased in 2015-Q1, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Lee Ainslie has maintained a strategic position in UTHR, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2019, adding 12,762 shares. Largest reduction occurred in Q3 2017, reducing 18,720 shares.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +1,219 | New Buy | 1,219 | $541.89 |
| Q4 2021 | -4,361 | Sold Out | 0 | $0.00 |
| Q3 2021 | -3,992 | Reduce 47.79% | 4,361 | $184.59 |
| Q2 2021 | +839 | Add 11.17% | 8,353 | $179.46 |
| Q1 2021 | +7,514 | New Buy | 7,514 | $167.29 |
| Q1 2020 | -14,781 | Sold Out | 0 | $0.00 |
| Q4 2019 | +2,019 | Add 15.82% | 14,781 | $88.09 |
| Q3 2019 | +12,762 | New Buy | 12,762 | $79.77 |
| Q3 2017 | -18,720 | Sold Out | 0 | $0.00 |
| Q2 2017 | -720 | Reduce 3.70% | 18,720 | $129.75 |
| Q1 2017 | -6,770 | Reduce 25.83% | 19,440 | $135.39 |
| Q4 2016 | +300 | Add 1.16% | 26,210 | $143.42 |
| Q3 2016 | -800 | Reduce 3.00% | 25,910 | $118.06 |
| Q2 2016 | +5,780 | Add 27.62% | 26,710 | $105.92 |
| Q1 2016 | +10,360 | Add 98.01% | 20,930 | $111.42 |
| Q4 2015 | +930 | Add 9.65% | 10,570 | $156.58 |
| Q3 2015 | +5,870 | Add 155.70% | 9,640 | $131.22 |
| Q2 2015 | -730 | Reduce 16.22% | 3,770 | $174.01 |
| Q1 2015 | +4,500 | New Buy | 4,500 | $172.44 |
Lee Ainslie's United Therapeutics Corporation Investment FAQs
Lee Ainslie first purchased United Therapeutics Corporation (UTHR) in Q1 2015, acquiring 4,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held United Therapeutics Corporation (UTHR) for 19 quarters since Q1 2015.
Lee Ainslie's largest addition to United Therapeutics Corporation (UTHR) was in Q3 2019, adding 12,762 shares worth $1.02 M.
According to the latest 13F filing for Q3 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 1,219 shares of United Therapeutics Corporation (UTHR), valued at approximately $660,564.
As of the Q3 2026 filing, United Therapeutics Corporation (UTHR) represents approximately 0.01% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in United Therapeutics Corporation (UTHR) was 26,710 shares, as reported at the end of Q2 2016.